Therapeutic cell engineering using surface-conjugated synthetic nanoparticles
By M. Stephan, J. Moon, Soong Ho Um, A. Bershteyn, D. Irvine. Nature Medicine, 2010
667 citations recorded by the source corpus.
A major limitation of cell therapies is the rapid decline in viability and function of the transplanted cells. Here we describe a strategy to enhance cell therapy via the conjugation of adjuvant drug–loaded nanoparticles to the surfaces of therapeutic cells. With this method of providing sustained pseudoautocrine stimulation to donor cells, we elicited marked enhancements in tumor elimination in a model of adoptive T cell therapy for cancer. We also increased the in vivo repopulation rate of hematopoietic stem cell grafts with very low doses of adjuvant drugs that were ineffective when given systemically. This approach is a simple and generalizable strategy to augment cytoreagents while minimizing the systemic side effects of adjuvant drugs. In addition, these results suggest therapeutic cells are promising vectors for actively targeted drug delivery.
Subfields: Genetics, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/6b5b85ad3730334621a278471b08b1a1e842251b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Oncology
Citations in the corpus
- Treating metastatic cancer with nanotechnology (2011, background): “The ability of cells to infiltrate deep tissue, cross biological membranes and target disease sites has made them attractive carriers of nanoparticle”
- Designer vaccine nanodiscs for personalized cancer immunotherapy (2016, positive): “CTL cytotoxicity was evaluated using the Lactate Dehydrogenase (LDH) Assay (CytoTox 96® Non-Radioactive Cytotoxicity Assay) in vitro with splenocytes from immunized mice and MC-38 target cells, as described previously 48,49 .”